Wegovy vs Zepbound: Comparing Benefits, Risks and Practical Fit
Wegovy and Zepbound are different medicines, not different strengths of the same injection. Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, which acts at GIP and GLP-1 receptors. Both require a personalized prescribing decision. [1,2]
This comparison focuses on injections for adult weight management and uses US brand names. Mounjaro also contains tirzepatide but should not be treated as an interchangeable name for the US weight-management product.
At a glance
| Criterion | What to compare |
|---|---|
| 1. Mechanism | Ingredient and receptor activity |
| 2. Evidence | Head-to-head results and their limits |
| 3. Treatment goal | Applicable indication and other health needs |
| 4. Tolerability / 5. History | Symptoms, contraindications and precautions |
| 6. Interactions / 7. Access | Other medicines, supply, cost and follow-up |
Use direct evidence without turning it into a guarantee
SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity but without diabetes. Average weight reduction favored tirzepatide. [3] That result is more informative than comparing unrelated trials, but it still describes the studied population and regimens. It does not establish that every individual should switch, predict your exact weight change or compare every formulation and dose available today.
Look for differences that matter to your life
One practical issue is oral hormonal contraception: the US Zepbound label advises a non-oral method or added barrier protection for four weeks after starting and for four weeks after each dose increase. [2] Discuss the exact plan with the prescribing team. Also review diabetes medicines, digestive symptoms and pregnancy plans. A medicine that looks preferable on a headline efficacy figure may not be the best fit after this review.
Compare the whole treatment pathway
Ask how side effects will be handled, how dose changes will be supervised and what happens if supply or coverage changes. Include appointments and monitoring in the affordability discussion, not just the first prescription. There is no do-it-yourself milligram conversion between these drugs. Do not overlap products or use leftover pens during a switch unless explicitly directed by the prescriber; coadministration with other GLP-1 treatments is not recommended in the relevant labels. [1,2]
Frequently asked questions
Is dual-receptor treatment automatically safer?
No. Mechanism alone cannot establish safety or the right choice for an individual.
Does the trial prove everyone should choose Zepbound?
No. Group averages must be weighed alongside indication, safety, tolerability, access and personal treatment goals.
Should I switch after a slow month?
First review the dose history, adherence and weight trend with the care team. One short interval does not establish treatment failure.
Related reading
- Wegovy, Saxenda, Mounjaro and Zepbound: What’s Different?
- Who Qualifies for GLP-1 Weight-Loss Medication? BMI and Health Criteria
- When Do GLP-1 Weight-Loss Drugs Start Working?
Korean version: 위고비 vs 마운자로: 효과 숫자보다 먼저 비교할 7가지 기준
Sources
- Wegovy US prescribing information · June 2026
- Zepbound US prescribing information · August 2026
- SURMOUNT-5: Tirzepatide compared with semaglutide
General health information, not an individual diagnosis or prescription. Discuss starting, changing or stopping treatment with your clinician. Seek immediate care for emergencies. Sources checked September 22, 2026; local product rules may differ.
